Multidisciplinary Management of Pancreatic Cancer
Authors:
- Joseph M. HermanJHJoseph M. Herman
- Christopher L. WolfgangCWChristopher L. Wolfgang
- Lei ZhengLZLei Zheng
- 1 April 2013
- journal article
- review article
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 22 (2) , 265-287
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II TrialJournal of Clinical Oncology, 2011
- A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinomaCancer Chemotherapy and Pharmacology, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic AdenocarcinomaAnnals of Surgery, 2011
- Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b–based chemoradiation: ACOSOG Trial Z05031Annals of Oncology, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Pancreatic CancerNew England Journal of Medicine, 2010
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2009
- Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704Journal of Clinical Oncology, 2008
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO studyAnnals of Oncology, 2008